VX-222/TELAPREVIR IN COMBINATION WITH PEGINTERFERON-ALFA-2A AND RIBAVIRIN IN TREATMENT-NAIVE GENOTYPE 1 HCV PATIENTS TREATED FOR 12 WEEKS: ZENITH STUDY, SVR12 INTERIM ANALYSIS

被引：0
|
作者：
Nelson, David R. [1 ]
Gane, Edward J. [2 ]
Jacobson, Ira M. [3 ]
Di Bisceglie, Adrian M. [4 ]
Alves, Katia [5 ]
Koziel, Margaret J. [5 ]
De Souza, Cynthia [5 ]
Kieffer, Tara L. [5 ]
George, Shelley [5 ]
Rosario, Maria [5 ]
Kauffman, Robert S. [5 ]
Sulkowski, Mark S. [6 ]
机构：
[1] Univ Florida, Coll Med, Gainesville, FL USA
[2] Auckland City Hosp, Auckland, New Zealand
[3] Weill Cornell Med Coll, New York, NY USA
[4] St Louis Univ, Sch Med, St Louis, MO USA
[5] Vertex Pharmacuet Inc, Cambridge, MA USA
[6] Johns Hopkins Univ, Baltimore, MD USA
来源：
HEPATOLOGY | 2011年 / 54卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：1435A / 1435A
页数：1
相关论文
共 50 条
  • [31] TELAPREVIR COMBINATION WITH PEGINTERFERON ALFA-2A/RIBAVIRIN IN HCV/HIV COINFECTED PATIENTS: 24-WEEK TREATMENT INTERIM ANALYSIS
    Sherman, Kenneth E.
    Rockstroh, Juergen K.
    Dieterich, Douglas T.
    Soriano, Vincent
    Girard, Pierre-Marie
    McCallister, Scott
    Adda, Nathalie
    Adiwijaya, Bambang S.
    Mahnke, Lisa
    Sulkowski, Mark S.
    HEPATOLOGY, 2011, 54 : 1431A - 1431A
  • [32] MODELING PREDICTS CLINICALLY MEANINGFUL SVR RATES IN GENOTYPE 1 TREATMENT-EXPERIENCED PATIENTS BASED ON RESULTS IN GENOTYPE 1 TREATMENT-NAIVE PATIENTS TREATED WITH SOFOSBUVIR plus PEGINTERFERON plus RIBAVIRIN FOR 12 WEEKS
    Muir, A.
    Nelson, D. R.
    Gordon, S. C.
    Feld, J. J.
    Patel, K.
    Lawitz, E.
    Sheikh, A. M.
    Brainard, D. M.
    Symonds, W. T.
    McHutchison, J. G.
    Bekele, B. N.
    Mangia, A.
    Gane, E. J.
    JOURNAL OF HEPATOLOGY, 2014, 60 (01) : S495 - S495
  • [33] Sustained Virologic Response (SVR12) in HCV Genotype 1 Patients Receiving Peginterferon Lambda in Combination With Ribavirin and Either Daclatasvir or Asunaprevir: Interim Results From the D-LITE Study
    Vierling, John M.
    Lataillade, Max
    Gane, Edward J.
    Lueth, Stefan
    Serfaty, Lawrence
    Taliani, Gloria
    Rustgi, Vinod K.
    Pol, Stanislas
    Diago, Moises
    Brunetto, Maurizio R.
    Rodriguez-Torres, Maribel
    Bruce, Robert D.
    Sola, Ricard
    Zeuzem, Stefan
    Gordon, Stuart C.
    Cohen, David S.
    Horga, Arantxa
    Srinivasan, Subasree
    Lopez-Talavera, Juan Carlos
    HEPATOLOGY, 2012, 56 (06) : 1522 - 1523
  • [34] Peginterferon alfa-2a and ribavirin for 12 or 24 weeks in patients with HCV genotype 2/3:: The nordynamic trial
    Lagging, Martin
    Pedersen, Court
    Buhl, Mads Rauning
    Faerkkilae, Martti
    Langeland, Nina
    Morch, Kristine
    Westin, Johan
    Alsioe, Asa
    Norkrans, Gunnar
    HEPATOLOGY, 2007, 46 (04) : 815A - 816A
  • [35] Treatment of chronic hepatitis C with telaprevir (TVR) in combination with peginterferon-alfa-2a with or without ribavirin: Further interim analysis results of the PROVE2 study
    Dusheiko, G. M.
    Hezode, C.
    Pol, S.
    Goeser, T.
    Bronowicki, J. -P.
    Bourliere, M.
    Buggisch, P.
    Serfaty, L.
    Berg, T.
    Couzige, P.
    Benhamou, Y.
    Forestier, N.
    Bengtsson, L.
    Gharakhanian, S.
    Kauffman, R.
    Alam, J.
    Ferenci, P.
    Pawlotsky, J. -M.
    Zeuzem, S.
    JOURNAL OF HEPATOLOGY, 2008, 48 : S26 - S26
  • [36] SAFETY ANTIVIRAL ACTIVITY OF THE HCV NON-NUCLEOSIDE POLYMERASE INHIBITOR VX-222 IN TREATMENT-NAIVE GENOTYPE 1 HCV-INFECTED PATIENTS
    Rodriguez-Torres, M.
    Lawitz, E.
    Conway, B.
    Kaita, K.
    Sheikh, A. M.
    Ghalib, R.
    Adrover, R.
    Cooper, C.
    Silva, M.
    Rosario, M.
    Bourgault, B.
    Proulx, L.
    McHutchison, J. G.
    JOURNAL OF HEPATOLOGY, 2010, 52 : S14 - S14
  • [37] Daclatasvir, an NS5A Replication Complex Inhibitor, Combined With Peginterferon Alfa-2a and Ribavirin in Treatment-Naive HCV-Genotype 1 or 4 Subjects: Phase 2b COMMAND-1 SVR12 Results
    Hezode, Christophe
    Hirschfield, Gideon M.
    Ghesquiere, Wayne
    Sievert, William
    Rodriguez-Torres, Maribel
    Shafran, Stephen D.
    Thuluvath, Paul J.
    Tatum, Harvey A.
    Waked, Imam
    Esmat, Gamal E.
    Lawitz, Eric
    Rustgi, Vinod K.
    Pol, Stanislas
    Weis, Nina
    Pockros, Paul
    Bourliere, Marc
    Serfaty, Lawrence
    Vierling, John M.
    Fried, Michael W.
    Weiland, Ola
    Brunetto, Maurizia R.
    Everson, Gregory T.
    Zeuzem, Stefan
    Kwo, Paul Y.
    Sulkowski, Mark S.
    Brau, Norbert
    Wind-Rotolo, Megan
    Liu, Zhaohui
    Hughes, Eric A.
    Schnittman, Steven M.
    Yin, Philip D.
    HEPATOLOGY, 2012, 56 : 553A - 554A
  • [38] Pre-treatment IP-10 levels and IL28B genotype as predictive markers for SVR in treatment-naive patients with genotype 1 HCV infection treated with telaprevir/peginterferon/ribavirin in the OPTIMIZE study
    Vijgen, Leen
    Dierynck, Inge
    Janssen, Katrien
    Talloen, Willem
    Gys, Luc
    Vanhoof, Greet
    Luo, Donghan
    De Meyer, Sandra
    Witek, James
    Aerssens, Jeroen
    HEPATOLOGY, 2013, 58 : 1096A - 1097A
  • [39] Safety and Sustained Viral Response of MK-5172 for 12 Weeks in Combination With Pegylated Interferon Alfa-2B and Ribavirin for 24 Weeks in HCV Genotype 1 Treatment-Naive Noncirrhotic Patients
    Marcellin, Patrick
    Vierling, John M.
    Bacon, Bruce R.
    Manns, Michael P.
    Fandozzi, Christine M.
    Gress, Jacqueline
    Gilbert, Christopher L.
    Hwang, Peggy
    Wahl, Janice
    Cooreman, Michael
    Mobashery, Niloufar
    HEPATOLOGY, 2012, 56 : 561A - 561A
  • [40] GS-5885+GS-9451+PEGINTERFERON AND RIBAVIRIN (PR) FOR SIX OR TWELVE WEEKS ACHIEVES HIGH SVR12 RATES IN TREATMENT-NAIVE GENOTYPE 1 IL28B CC PATIENTS
    Thompson, A.
    Han, S.
    Shiffman, M. L.
    Rossaro, L.
    Ghalib, R.
    Beavers, K.
    Pianko, S.
    Wu, X.
    Pang, P. S.
    Rossi, S.
    McHutchison, J.
    Muir, A.
    Lee, S.
    George, J.
    JOURNAL OF HEPATOLOGY, 2013, 58 : S29 - S29
12345